Generic placeholder image

Endocrine, Metabolic & Immune Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5303
ISSN (Online): 2212-3873

Book of Abstract

10 Cases of Nonresponse to Laser Thermoablation from a Series of 187 Patients: Histological Outcomes after Surgery and Related Evaluations

In Press, (this is not the final "Version of Record"). Available online 26 July, 2024
Author(s): Sansone D., Garino F., Di Noi F., Breda M., Bonelli N., Visconti F.*, Quaglino F. and Oleandri S.E.
Published on: 26 July, 2024

DOI: 10.2174/0118715303322640240722112506

Price: $95

Abstract

Background: Thyroid thermoablative techniques have been developed as an alternative to surgery for the treatment of symptomatic benign nodes, with the advantage of being minimally invasive, repeatable, with a minimal complication rate, and avoiding the perioperative risks and irreversible consequences of surgery.

Methods: A series of patients undergoing laser thermoablation by the same team of endocrinologists operating in 2 centers from May 2016 to December 2022 is presented. The procedure was performed in patients with compressive symptomatology determined by a thyroid node typed TIR 2, or TIR 3A with rejection of the surgical option. We analyzed cases that required surgery because of persistent compressive symptoms, reduction failure, or increase in volume. Results: From May 2016 to December 2022, 207 thermoablative procedures were performed (187 patients). Single ablative session was unresolved in 28 patients (15%). The proportion of nodes with TIR 3A cytology was significantly higher (21.4 vs 7.0%). In this group, the response in terms of volumetric reduction 6 months after the procedure was significantly lower (5.7% vs 50%). Ten patients (5.3%) underwent surgery, whose histological outcome demonstrated malignancy in 50% of cases.

Conclusions: Data show the importance of timely re-evaluation with referral to surgical treatment for patients presenting a less than 20% volume reduction 6 months after thermoablation, in order to ensure promptly effective treatment of misrecognized malignancies.


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy